Get the Stockscreener App
31.00
3.33%
1.00
After Hours:
31.00
Quince Therapeutics Inc stock is traded at $31.00, with a volume of 10,335.
It is up +3.33% in the last 24 hours and up +0.23% over the past month.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
See More
Previous Close:
$30.00
Open:
$30.4
24h Volume:
10,335
Relative Volume:
0.35
Market Cap:
$31.53M
Revenue:
-
Net Income/Loss:
$-33.04M
P/E Ratio:
-3.4057
EPS:
-9.1023
Net Cash Flow:
$-39.66M
1W Performance:
+5.16%
1M Performance:
+0.23%
6M Performance:
+51.96%
1Y Performance:
-90.49%
1-Day Range:
$29.98
$31.00
1-Week Range:
$28.54
$32.99
52-Week Range:
$15.10
$909.98
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
31.00 | 31.53M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
Quince Therapeutics forms Scientific Advisory Board to advance LAM-001 - scanx.trade
Rodman & Renshaw initiates Quince Therapeutics stock with buy rating - Investing.com
Rodman & Renshaw initiates Quince Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Quince Therapeutics, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (QNCX) - Traders Union
Quince Therapeutics, Inc. (QNCX) Earnings Date, Reports and Estimates - Traders Union
Live Quince Therapeutics, Inc. (QNCX) Technical Analysis - Traders Union
Quince Therapeutics, Inc. (QNCX) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Quince Therapeutics stock falls 3.83 percent on Nasdaq - ad-hoc-news.de
QNCX Upgraded by Citizens -- Price Target Announced at $77.00 - GuruFocus
Citizens JMP Upgrades Quince Therapeutics(QNCX.US) to Buy Rating, Announces Target Price $77 - Moomoo
Citizens upgrades Quince Therapeutics stock rating on rare disease pipeline By Investing.com - Investing.com Australia
Citizens upgrades Quince Therapeutics stock rating on rare disease pipeline - Investing.com
Quince Therapeutics, Inc. (QNCX) Stock Price History & Data - Traders Union
QNCX Should I Buy - Intellectia AI
Quince Therapeutics stock prepares for LAM-001 KOL event as shares trade below recent highs - ad-hoc-news.de
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026 - Yahoo Finance
Quince Therapeutics, Inc.Common Stock (Nasdaq:QNCX) Stock Quote - The Chronicle-Journal
Quince Therapeutics Divests Italian Subsidiary, Refocuses Strategy - TipRanks
Quince Therapeutics at Cantor conference: inhaled rapamycin gains traction By Investing.com - Investing.com South Africa
Quince Therapeutics at Cantor conference: inhaled rapamycin gains traction - Investing.com India
Quince Therapeutics Faces Nasdaq Listing Compliance Challenges - The Globe and Mail
Quince Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Quince Therapeutics to Participate in September 2026 Investor Conferences - Quiver Quantitative
$Quince Therapeutics (QNCX.US)$ - Moomoo
QNCX stock holds steady as Quince Therapeutics pursues strategic alternatives - ad-hoc-news.de
Quince Therapeutics Announces Planned Presidential Leadership Transition - The Globe and Mail
Quince Therapeutics' Charles Ryan to Depart as President, Last Day Sept 8, 2026 - TradingView
Quince Therapeutics, Inc. Announces Resignation of Charles Ryan from President, Effective September 8, 2026 - marketscreener.com
Quince Therapeutics, Inc. SEC Filing (Aug 25, 2026) - Stock Titan
Craig-Hallum Initiates Quince Therapeutics at Buy With $68 Price Target - Yahoo Finance
Quince (QNCX) Results at a Glance: The Available Earnings Metric Delivers a Beat; Market Move: Shares Finish 7.12% Lower in the Available RecordEarnings Seasonality - vinanet.vn
Balyasny Asset Management L.P. Initiates New Position in Quince Therapeutics Inc (QNCX) - GuruFocus
Craig-Hallum Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $68 - Moomoo
Quince (QNCX) Chart: Slides 0.90% to $34.26 at the Close; Price Setup: Price Remains Between $32.55 Support and $35.97 Resistance in the Available RecordSentiment Divergence - vinanet.vn
Craig-Hallum Initiates Coverage on Quince Therapeutics (QNCX) wi - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
LifeSci Capital Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Cuts Target Price to $98 - Moomoo
Quince Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
QNCX Reiterated by Cantor Fitzgerald -- Price Target Maintained at $70 - gurufocus.com
Quince Plans Shareholder Vote on Major Stock Issuance - The Globe and Mail
Form 8K Quince Therapeutics Inc For: 17 August By Investing.com - Investing.com Nigeria
Quince Therapeutics Closes Orphai Acquisition With $115M PIPE Financing - Minichart
Quince Therapeutics plans special meeting to vote on share issuance and potential change of control - Investing.com
Quince Therapeutics to seek shareholder OK for Series C conversion, adding ~11M shares and reclassifying $6.3M warrants - TradingView
Ikarian Capital discloses 9.0% Quince Therapeutics (QNCX) ownership in Schedule 13G - Stock Titan
Nantahala Capital (QNCX) reports 0% stake in Quince Therapeutics in latest 13G/A - Stock Titan
Quince Therapeutics (QNCX) Jumps 5% to $34.04 as Bulls Target $35.74 ResistanceBlue Chip Entry Points - vinanet.vn
Quince Therapeutics (QNCX) books $39.6M loss but lifts cash to $116M - Stock Titan
Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Quince Therapeutics, Inc. (NASDAQ: QNCX) Stock Price, News & Analysis - Kalkine
Quince Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):